Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mallinckrodt, FTC And The Antitrust Risks Of Pipeline Acquisitions

Executive Summary

Acthar case could discourage firms looking to enhance franchises by acquiring drugs in development after FTC alleges firm purchased a would-be competitor to keep it off the US market. Is this something else we can blame on Martin Shkreli?

You may also be interested in...

Shkreli's Indictment May Help Industry Escape His Shadow

Having a pharma CEO arrested usually wouldn't be good news for industry – except it’s this guy.

Court Tosses Suit Over Lundbeck's Purchase Of Two Drugs Used In Premature Infants

Federal judge finds NeoProfen and Indocin IV are not in the same product market; FTC and Minnesota filed suit after Lundbeck raised the price of Indocin, then the only approved drug, by 1,300%.

Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data

After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts